David Amsellem
Stock Analyst at Piper Sandler
(3.83)
# 888
Out of 4,412 analysts
86
Total ratings
46.67%
Success rate
9.33%
Average return
Main Sectors:
25 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AQST Aquestive Therapeutics | Initiates: Overweight | $10 | $4.07 | +145.70% | 1 | Apr 11, 2024 | |
| ALKS Alkermes | Reiterates: Overweight | $39 | $24.68 | +58.02% | 6 | Apr 1, 2024 | |
| VTRS Viatris | Reiterates: Neutral | $11 → $13 | $11.57 | +12.36% | 5 | Mar 28, 2024 | |
| AMRX Amneal Pharmaceuticals | Maintains: Overweight | $6 → $8 | $5.87 | +36.29% | 3 | Mar 21, 2024 | |
| JAZZ Jazz Pharmaceuticals | Reiterates: Overweight | $171 → $188 | $109.46 | +71.75% | 4 | Mar 20, 2024 | |
| AVDL Avadel Pharmaceuticals | Maintains: Overweight | $18 → $23 | $17.81 | +29.14% | 3 | Mar 5, 2024 | |
| RVNC Revance Therapeutics | Maintains: Overweight | $42 → $20 | $3.40 | +488.24% | 5 | Feb 29, 2024 | |
| SUPN Supernus Pharmaceuticals | Maintains: Overweight | $45 → $41 | $30.07 | +36.35% | 9 | Feb 28, 2024 | |
| COLL Collegium Pharmaceutical | Reiterates: Overweight | $37 → $39 | $36.42 | +7.08% | 2 | Feb 23, 2024 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Overweight | $20 → $21 | $7.82 | +168.54% | 3 | Feb 16, 2024 | |
| TEVA Teva Pharmaceutical | Upgrades: Overweight | $12 → $19 | $13.81 | +37.58% | 5 | Feb 12, 2024 | |
| AXSM Axsome Therapeutics | Maintains: Overweight | $90 → $113 | $71.71 | +57.58% | 3 | Jan 16, 2024 | |
| CERE Cerevel Therapeutics Holdings | Downgrades: Neutral | $33 → $45 | $42.47 | +5.96% | 2 | Dec 7, 2023 | |
| OGN Organon & Co. | Maintains: Overweight | $32 → $22 | $18.55 | +18.60% | 4 | Nov 22, 2023 | |
| CARA Cara Therapeutics | Downgrades: Neutral | $12 → $1 | $0.68 | +46.13% | 3 | Nov 14, 2023 | |
| XERS Xeris Biopharma Holdings | Maintains: Overweight | $5 → $4 | $1.75 | +128.57% | 2 | Nov 10, 2023 | |
| PCRX Pacira BioSciences | Maintains: Overweight | $50 → $42 | $26.33 | +59.51% | 6 | Nov 3, 2023 | |
| NBIX Neurocrine Biosciences | Maintains: Neutral | $95 → $100 | $135.99 | -26.47% | 4 | Nov 1, 2023 | |
| HRMY Harmony Biosciences Holdings | Maintains: Overweight | $72 → $42 | $29.32 | +43.25% | 3 | Oct 16, 2023 | |
| OPTN OptiNose | Maintains: Overweight | $4 → $3 | $0.86 | +248.68% | 1 | Aug 11, 2023 | |
| EGRX Eagle Pharmaceuticals | Downgrades: Underweight | $26 → $17 | $4.16 | +308.65% | 2 | Aug 9, 2023 | |
| CORT Corcept Therapeutics | Maintains: Overweight | $27 → $31 | $22.80 | +35.96% | 2 | Aug 3, 2023 | |
| AMPH Amphastar Pharmaceuticals | Maintains: Overweight | $43 → $40 | $41.11 | -2.70% | 3 | Oct 25, 2022 | |
| BHC Bausch Health Companies | Maintains: Neutral | $7 → $6 | $8.71 | -31.11% | 3 | Sep 9, 2022 | |
| EVFM Evofem Biosciences | Maintains: Overweight | $3,750 → $250 | $0.02 | +1,492,437.31% | 2 | May 25, 2022 |
Aquestive Therapeutics
Apr 11, 2024
Initiates: Overweight
Price Target: $10
Current: $4.07
Upside: +145.70%
Alkermes
Apr 1, 2024
Reiterates: Overweight
Price Target: $39
Current: $24.68
Upside: +58.02%
Viatris
Mar 28, 2024
Reiterates: Neutral
Price Target: $11 → $13
Current: $11.57
Upside: +12.36%
Amneal Pharmaceuticals
Mar 21, 2024
Maintains: Overweight
Price Target: $6 → $8
Current: $5.87
Upside: +36.29%
Jazz Pharmaceuticals
Mar 20, 2024
Reiterates: Overweight
Price Target: $171 → $188
Current: $109.46
Upside: +71.75%
Avadel Pharmaceuticals
Mar 5, 2024
Maintains: Overweight
Price Target: $18 → $23
Current: $17.81
Upside: +29.14%
Revance Therapeutics
Feb 29, 2024
Maintains: Overweight
Price Target: $42 → $20
Current: $3.40
Upside: +488.24%
Supernus Pharmaceuticals
Feb 28, 2024
Maintains: Overweight
Price Target: $45 → $41
Current: $30.07
Upside: +36.35%
Collegium Pharmaceutical
Feb 23, 2024
Reiterates: Overweight
Price Target: $37 → $39
Current: $36.42
Upside: +7.08%
Ironwood Pharmaceuticals
Feb 16, 2024
Maintains: Overweight
Price Target: $20 → $21
Current: $7.82
Upside: +168.54%
Teva Pharmaceutical
Feb 12, 2024
Upgrades: Overweight
Price Target: $12 → $19
Current: $13.81
Upside: +37.58%
Axsome Therapeutics
Jan 16, 2024
Maintains: Overweight
Price Target: $90 → $113
Current: $71.71
Upside: +57.58%
Cerevel Therapeutics Holdings
Dec 7, 2023
Downgrades: Neutral
Price Target: $33 → $45
Current: $42.47
Upside: +5.96%
Organon & Co.
Nov 22, 2023
Maintains: Overweight
Price Target: $32 → $22
Current: $18.55
Upside: +18.60%
Cara Therapeutics
Nov 14, 2023
Downgrades: Neutral
Price Target: $12 → $1
Current: $0.68
Upside: +46.13%
Xeris Biopharma Holdings
Nov 10, 2023
Maintains: Overweight
Price Target: $5 → $4
Current: $1.75
Upside: +128.57%
Pacira BioSciences
Nov 3, 2023
Maintains: Overweight
Price Target: $50 → $42
Current: $26.33
Upside: +59.51%
Neurocrine Biosciences
Nov 1, 2023
Maintains: Neutral
Price Target: $95 → $100
Current: $135.99
Upside: -26.47%
Harmony Biosciences Holdings
Oct 16, 2023
Maintains: Overweight
Price Target: $72 → $42
Current: $29.32
Upside: +43.25%
OptiNose
Aug 11, 2023
Maintains: Overweight
Price Target: $4 → $3
Current: $0.86
Upside: +248.68%
Eagle Pharmaceuticals
Aug 9, 2023
Downgrades: Underweight
Price Target: $26 → $17
Current: $4.16
Upside: +308.65%
Corcept Therapeutics
Aug 3, 2023
Maintains: Overweight
Price Target: $27 → $31
Current: $22.80
Upside: +35.96%
Amphastar Pharmaceuticals
Oct 25, 2022
Maintains: Overweight
Price Target: $43 → $40
Current: $41.11
Upside: -2.70%
Bausch Health Companies
Sep 9, 2022
Maintains: Neutral
Price Target: $7 → $6
Current: $8.71
Upside: -31.11%
Evofem Biosciences
May 25, 2022
Maintains: Overweight
Price Target: $3,750 → $250
Current: $0.02
Upside: +1,492,437.31%